Illumina, Inc. $ILMN Holdings Lifted by 53 House LLP

Key Points

• 53 House LLP increased its holdings in Illumina, Inc. by 71.2%, making it the fund's third largest position with 152,073 shares valued at approximately $12.06 million.
• Illumina reported an EPS of $1.19 for the last quarter, exceeding analysts' expectations of $1.02, while experiencing a 4.8% decline in year-over-year revenue.
• Wall Street analysts have mixed ratings on Illumina, with an average target price of $124.58, where seven analysts rated it as a Buy and eleven assigned a Hold rating.

53 House LLP increased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 71.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 152,073 shares of the life sciences company's stock after purchasing an additional 63,249 shares during the quarter. Illumina makes up about 10.7% of 53 House LLP's holdings, making the stock its 3rd biggest position. 53 House LLP owned approximately 0.10% of Illumina worth $12,065,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Fourth Dimension Wealth LLC purchased a new position in Illumina during the fourth quarter worth about $40,000. Rakuten Securities Inc. boosted its stake in Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after acquiring an additional 270 shares during the last quarter. Center for Financial Planning Inc. purchased a new position in Illumina in the first quarter valued at about $33,000. PFS Partners LLC boosted its stake in Illumina by 400.0% in the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after acquiring an additional 400 shares during the last quarter. Finally, Golden State Wealth Management LLC boosted its stake in Illumina by 123.2% in the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock valued at $42,000 after acquiring an additional 292 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Performance

Shares of ILMN stock opened at $101.80 on Friday. The stock has a market capitalization of $15.65 billion, a P/E ratio of 12.89, a PEG ratio of 2.29 and a beta of 1.37. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The firm's 50 day moving average is $98.18 and its 200 day moving average is $88.88. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. The company had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. Illumina's revenue was down 4.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of research analyst reports. Canaccord Genuity Group boosted their target price on shares of Illumina from $99.00 to $105.00 and gave the company a "hold" rating in a research note on Friday, August 1st. Guggenheim dropped their target price on shares of Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Daiwa Capital Markets cut shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 target price on the stock. in a research note on Tuesday, August 12th. Stephens set a $110.00 target price on shares of Illumina and gave the company an "overweight" rating in a research note on Monday, August 4th. Finally, Wall Street Zen cut shares of Illumina from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Seven equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $124.58.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.